Omalizumab: When the non-responder is a late-responder

F. Menzella, N. Facciolongo, C. Castagnetti, A. Simonazzi, L. Zucchi

Research output: Contribution to journalArticle

Abstract

Omalizumab is an anti-IgE monoclonal antibody available since 2006 for the treatment of GINA step 4 asthma. We studied a 41-year old male who has been suffering from severe steroid-resistant asthma with severe co-morbidity and treated with Omalizumab. He was found to be non-responder to the treatment until the 48th week, starting from which we began to see a distinct improvement in the symptoms and all the correlated parameters, in addition to remission of the co-existent allergy to milk. Conclusions: we wish to point out the late response to Omalizumab, which occurred way beyond the times envisaged in literature. It seems possible that some patients are late responders to the drug.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalEuropean Annals of Allergy and Clinical Immunology
Volume41
Issue number5
Publication statusPublished - Oct 2009

Fingerprint

Asthma
Milk Hypersensitivity
Steroids
Monoclonal Antibodies
Morbidity
Therapeutics
Pharmaceutical Preparations
Omalizumab
anti-IgE antibodies

Keywords

  • Omalizumab
  • Quality of life
  • Spirometry
  • Steroid-resistant asthma

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Menzella, F., Facciolongo, N., Castagnetti, C., Simonazzi, A., & Zucchi, L. (2009). Omalizumab: When the non-responder is a late-responder. European Annals of Allergy and Clinical Immunology, 41(5), 155-159.

Omalizumab : When the non-responder is a late-responder. / Menzella, F.; Facciolongo, N.; Castagnetti, C.; Simonazzi, A.; Zucchi, L.

In: European Annals of Allergy and Clinical Immunology, Vol. 41, No. 5, 10.2009, p. 155-159.

Research output: Contribution to journalArticle

Menzella, F, Facciolongo, N, Castagnetti, C, Simonazzi, A & Zucchi, L 2009, 'Omalizumab: When the non-responder is a late-responder', European Annals of Allergy and Clinical Immunology, vol. 41, no. 5, pp. 155-159.
Menzella F, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Omalizumab: When the non-responder is a late-responder. European Annals of Allergy and Clinical Immunology. 2009 Oct;41(5):155-159.
Menzella, F. ; Facciolongo, N. ; Castagnetti, C. ; Simonazzi, A. ; Zucchi, L. / Omalizumab : When the non-responder is a late-responder. In: European Annals of Allergy and Clinical Immunology. 2009 ; Vol. 41, No. 5. pp. 155-159.
@article{9dc36b68318442bd82d9cfbef4f878fa,
title = "Omalizumab: When the non-responder is a late-responder",
abstract = "Omalizumab is an anti-IgE monoclonal antibody available since 2006 for the treatment of GINA step 4 asthma. We studied a 41-year old male who has been suffering from severe steroid-resistant asthma with severe co-morbidity and treated with Omalizumab. He was found to be non-responder to the treatment until the 48th week, starting from which we began to see a distinct improvement in the symptoms and all the correlated parameters, in addition to remission of the co-existent allergy to milk. Conclusions: we wish to point out the late response to Omalizumab, which occurred way beyond the times envisaged in literature. It seems possible that some patients are late responders to the drug.",
keywords = "Omalizumab, Quality of life, Spirometry, Steroid-resistant asthma",
author = "F. Menzella and N. Facciolongo and C. Castagnetti and A. Simonazzi and L. Zucchi",
year = "2009",
month = "10",
language = "English",
volume = "41",
pages = "155--159",
journal = "Allergie et Immunologie",
issn = "0397-9148",
publisher = "Mattioli 1885 S.p.A.",
number = "5",

}

TY - JOUR

T1 - Omalizumab

T2 - When the non-responder is a late-responder

AU - Menzella, F.

AU - Facciolongo, N.

AU - Castagnetti, C.

AU - Simonazzi, A.

AU - Zucchi, L.

PY - 2009/10

Y1 - 2009/10

N2 - Omalizumab is an anti-IgE monoclonal antibody available since 2006 for the treatment of GINA step 4 asthma. We studied a 41-year old male who has been suffering from severe steroid-resistant asthma with severe co-morbidity and treated with Omalizumab. He was found to be non-responder to the treatment until the 48th week, starting from which we began to see a distinct improvement in the symptoms and all the correlated parameters, in addition to remission of the co-existent allergy to milk. Conclusions: we wish to point out the late response to Omalizumab, which occurred way beyond the times envisaged in literature. It seems possible that some patients are late responders to the drug.

AB - Omalizumab is an anti-IgE monoclonal antibody available since 2006 for the treatment of GINA step 4 asthma. We studied a 41-year old male who has been suffering from severe steroid-resistant asthma with severe co-morbidity and treated with Omalizumab. He was found to be non-responder to the treatment until the 48th week, starting from which we began to see a distinct improvement in the symptoms and all the correlated parameters, in addition to remission of the co-existent allergy to milk. Conclusions: we wish to point out the late response to Omalizumab, which occurred way beyond the times envisaged in literature. It seems possible that some patients are late responders to the drug.

KW - Omalizumab

KW - Quality of life

KW - Spirometry

KW - Steroid-resistant asthma

UR - http://www.scopus.com/inward/record.url?scp=72449182124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449182124&partnerID=8YFLogxK

M3 - Article

C2 - 20101930

AN - SCOPUS:72449182124

VL - 41

SP - 155

EP - 159

JO - Allergie et Immunologie

JF - Allergie et Immunologie

SN - 0397-9148

IS - 5

ER -